Heparin in calcification prevention of porcine pericardial bioprostheses
Source abstract
Abstract
Calcific degeneration is the main cause of failure of glutaraldehyde-treated xenograft heart valve substitutes implanted in humans. Coupling of heparin through an intermediate surface-bound substrate containing amino groups showed complete prevention of calcification of glutaraldehyde-treated porcine pericardium implanted subdermally in weanling rats for 5 months (heparin bonded pericardium: calcium, 0.625 +/- 0.24 mg g(-1); glutaraldehyde-only-treated pericardium: calcium, 228.32 +/- 37.39 mg g(-1); P < 0.0001). Conceivably, inactivation of unpaired aldehyde moieties present in bioprostheses after exposure to glutaraldehyde by amino compounds followed by blocking the potential binding sites of the graft with a surface modifying agent like heparin would be the key steps in the prevention of calcification and degeneration of glutaraldehyde-treated biological tissue grafts.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Information Retrieval and Data Mining · SMEs Development and Digital Marketing · Decision Support System Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Biological valves: stented and unstented
2. A comparison of replacement and reconstruction in patients with mitral regurgitation10.1016/S0022-5223(19)36345-7 ↗
3. Indications and limitations of aortic valve reconstruction10.1016/0003-4975(91)90904-5 ↗
4. Stability of mitral reconstructive surgery at 10–12 years for predominantly rheumatic valvular disease
5. Results of mitral valve reconstruction
6. Pregnancy in patients with a porcine valve bioprosthesis10.1016/0002-9149(82)90416-7 ↗
7. Pregnancy and mechanical valve prostheses: a high risk situation for mother and the fetus10.1016/S0003-4975(10)60488-2 ↗
8. Pregnancy and child bearing in a population with biological valvular prostheses10.1016/S0022-5223(19)36549-3 ↗
9. Degeneration in porcine bioprosthetic cardiac valves: incidence of primary tissue failure among 938 bioprostheses at risk10.1016/0002-9149(84)90637-4 ↗
10. Porcine cardiac bioprostheses: evaluation of long-term results in 990 patients10.1016/S0003-4975(10)62587-8 ↗
11. The Carpentier-Edwards supraannular porcine bioprosthesis. A new generation tissue valve with excellent intermediate clinical performance10.1016/S0022-5223(19)35221-3 ↗
12. Durability of porcine valves at fifteen years in a representative North American patient population10.1016/S0022-5223(19)35024-X ↗
13. Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups10.1016/S0003-4975(10)65888-2 ↗
14. The porcine bioprosthetic heart valve: experience at fifteen years10.1016/S0003-4975(10)62850-0 ↗
15. Tenyear experience with the porcine bioprosthetic valves: interrelationship of valve survival and patient survival in 1050 valve replacements10.1016/0003-4975(90)90240-7 ↗
16. Late failure of porcine valve heterografts in children10.1016/S0022-5223(19)38101-2 ↗
17. The outcome of antibiotic sterilised homografts used in Fontan procedure10.1016/1010-7940(93)90067-L ↗
18. Failure of cryopreserved homograft valved conduits in the pulmonary circulation
19. Degeneration of aortic valve allografts in young recipients10.1016/S0022-5223(19)34168-6 ↗
20. Transplantation of aortic and pulmonary allografts, enhanced viability of endothelial cells by cryopreservation. Importance of histocompatibility10.1111/jocs.1987.2.1s.209 ↗
21. Anticalcification treatment of pericardial prostheses10.1016/0142-9612(94)90226-7 ↗
22. Prevention of calcification of tissue valve10.1111/j.1525-1594.1994.tb03314.x ↗
23. Prevention of calcification of heart valve bioprosthesis: an experimental study in rat10.1016/0003-4975(95)00256-K ↗
24. Use of the glutaraldehyde-treated chitosan post-treated porcine pericardium as a pericardial substitute10.1016/0142-9612(96)85909-6 ↗
25. Efficacy of the chitosan posttreatment in calcification prevention of the glutaraldehyde treated porcine aortic noncoronary cusp implanted in the right ventricular outflow tract in dogs10.1111/j.1525-1594.1996.tb04537.x ↗
26. Bilateral enlargement of the aortic valve ring for valve replacement in children. New operative technique10.1016/S0022-5223(19)36552-3 ↗
27. Semilunar valve replacement with a cylindrical valve10.1111/j.1540-8191.1993.tb00427.x ↗
28. New surgical technique for repair of ventricular septal perforation10.1016/0003-4975(95)00650-A ↗
29. Comparative electron microscopic study of bovine, porcine and human parietal pericardium, as materials for cardiac valve bioprostheses
30. Relevance of immunogenic reactions for tissue failure of bioprosthetic heart valves10.1016/0003-4975(95)00291-R ↗
31. Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups10.1016/S0003-4975(10)65932-2 ↗
32. Bioprosthetic heart valve pathology: clinico-pathological features of valve failure and pathobiology of calcification
33. Posttreatment with amino compounds effective in prevention of calcification of glutaraldehyde treated pericardium10.1111/j.1525-1594.1994.tb02223.x ↗
34. Onset and progression of experimental bioprosthetic heart valve calcification
35. Inhibition of rat arterial smooth muscle cell proliferation by heparin: II. In vitro studies10.1161/01.RES.47.4.578 ↗
36. The observation of heparin on endothelium after injection10.1016/0049-3848(76)90262-0 ↗
37. Evidence for a heparin-induced conformational change of antithrombin III10.1016/0006-291X(77)90374-6 ↗
38. Tumor cell volume changes in vivo induced by heparin
39. Heparin: pharmacological potentials from atherosclerosis to asthma10.1016/0306-3623(94)00170-R ↗
40. Inhibition of smooth muscle cell proliferation and experimental angioplasty restenosis by beta-cyclodextrin tetradecasulfate10.1161/01.ATV.13.6.924 ↗
41. Heparin as a therapy for atherosclerosis: preliminary observations on the intrapulmonary administration of low-dose heparin in the morning versus evening gauged by its effect on blood variables10.3109/07420529109063928 ↗
42. Heparin and atherosclerosis: an investigative report on the treatment of atherosclerosis10.1016/0753-3322(90)90133-T ↗
43. A new method for covalent coupling of heparin and other glycosaminoglycans to substances containing primary amino groups10.1016/0008-6215(83)88103-8 ↗